Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies

Journal of Infection

Volumn 73, Issue 4, 2016, Pages 336-345

  Satlin, Michael J ^a   Cohen, Nina ^b   Ma, Kevin C ^a   Gedrimaite, Zivile ^b   Soave, Rosemary ^a   Askin, Gülce ^a   Chen, Liang ^c   Kreiswirth, Barry N ^c   Walsh, Thomas J ^a   Seo, Susan K ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Bacteremia; Carbapenem resistant Enterobacteriaceae; Hematologic malignancies; Neutropenic patients; Outcomes; Prevalence; Risk factors

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; GLUCOCORTICOID; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD CULTURE; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CONTROLLED STUDY; FEMALE; GRAM NEGATIVE SEPSIS; HEMATOLOGIC MALIGNANCY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NEUTROPENIA; NEW YORK; NONHUMAN; PREVALENCE; PROGNOSIS; ANTIBIOTIC RESISTANCE; BACTEREMIA; CASE CONTROL STUDY; COMPLICATION; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HEMATOLOGIC DISEASE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; RISK FACTOR; YOUNG ADULT;

ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; CARBAPENEMS; CASE-CONTROL STUDIES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; NEW YORK CITY; PREVALENCE; RISK FACTORS; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION; YOUNG ADULT;

EID: 84978878033     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2016.07.002     Document Type: Article

References (27)

1. 1 Klastersky, J., Ameye, L., Maertens, J., Georgala, A., Muanza, F., Aoun, M., et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents(Suppl. 1), 2007, S51–S59.
2. 2 Freifeld, A.G., Bow, E.J., Sepkowitz, K.A., Boeckh, M.J., Ito, J.I., Mullen, C.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52 (2011), e36–e93.
3. 3 Nordmann, P., Naas, T., Poirel, L., Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Inf Dis 17 (2011), 1791–1798.
4. 4 Satlin, M.J., Jenkins, S.G., Walsh, T.J., The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis 58 (2014), 1274–1283.
5. 5 Satlin, M.J., Calfee, D.P., Chen, L., Fauntleroy, K.A., Wilson, S.J., Jenkins, S.G., et al. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma 54 (2013), 799–806.
6. 6 Centers for Disease Control and Prevention. Device-associated module: bloodstream infection event. Available at: http://www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABScurrent.pdf. Accessed 10 Nov 2015.
7. 7 Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987), 373–383.
8. 8 Levy, M.M., Fink, M.P., Marshall, J.C., Abraham, E., Angus, D., Cook, D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 (2003), 1250–1256.
9. 9 Paterson, D.L., Ko, W.C., Von Gottberg, A., Mohapatra, S., Casellas, J.M., Goossens, H., et al. International prospective study of Klebsiella pneumoniae bacteremia: implications for extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 140 (2004), 26–32.
10. 10 Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI M100-S22, 2012, CLSI, Wayne, PA.
11. 11 Woodford, N., Fagan, E.J., Ellington, M.J., Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum (beta)-lactamases. J Antimicrob Chemother 57 (2006), 154–155.
12. 12 Poirel, L., Walsh, T.R., Cuvillier, V., Nordmann, P., Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 70 (2011), 119–123.
13. KPC) variants. J Clin Microbiol 49 (2011), 579–585.
14. 14 Kaczmarek, F.M., Dib-Hajj, F., Shang, W., Gootz, T.D., High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe. Antimicrob Agents Chemother 50 (2006), 3396–3406.
15. 15 Bratu, S., Landman, D., Haag, R., Recco, R., Eramo, A., Alam, M., et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 165 (2005), 1430–1435.
16. 16 Marin, M., Gudiol, C., Ardanuy, C., Garcia-Vidal, C., Jimenez, L., Domingo-Domenech, E., et al. Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumors with bloodstream infection. Clin Microbiol Infect 21 (2015), 583–590.
17. 17 Schimpff, S.C., Greene, W.H., Young, V.M., Wiernik, P.H., Pseudomonas septicemia: incidence, epidemiology, prevention and therapy in patients with advanced cancer. Eur J Cancer 9 (1973), 449–455.
18. 18 Calfee, D., Jenkins, S.G., Use of active surveillance cultures to detect asymptomatic colonization with carbapenem-resistant Klebsiella pneumoniae in intensive care unit patients. Infect Control Hosp Epidemiol 29 (2008), 966–968.
19. 19 Debby, B.D., Ganor, O., Yasmin, M., David, L., Nathan, K., Ilana, T., et al. Epidemiology of carbapenem-resistant Klebsiella pneumoniae colonization in an intensive care unit. Eur J Clin Microbiol Infect Dis 31 (2012), 1811–1817.
20. 20 Lin, M.Y., Weinstein, R.A., Hota, B., Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother 52 (2008), 3188–3194.
21. 21 Trecarichi, E.M., Tumbarello, M., Spanu, T., Caira, M., Fianchi, L., Chiusolo, P., et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli and in patients with hematological malignancies. J Infect 58 (2009), 299–307.
22. 22 Ledeboer, N.A., Lopansri, B.K., Dhiman, N., Cavagnolo, R., Carroll, K.C., Granato, P., et al. Identification of Gram-negative bacteria and genetic resistance determinants from positive blood culture broths by use of the Verigene Gram-negative blood culture multiplex microarray-based molecular assay. J Clin Microbiol 53 (2015), 2460–2472.
23. 23 Blaschke, A.J., Heyrend, C., Byington, C.L., Fisher, M.A., Barker, E., Garrone, N.F., et al. Rapid identification of pathogens from positive blood cultures by multiplex polymerase chain reaction using the FilmArray system. Diagn Microbiol Infect Dis 74 (2012), 349–355.
24. 24 Pogue, J.M., Lee, J., Marchaim, D., Yee, V., Zhao, J.J., Chopra, T., et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53 (2011), 879–884.
25. 25 Rigatto, M.H., Behle, T.F., Falci, D.R., Freitas, T., Lopes, N.T., Nunes, M., et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicenter prospective cohort study. J Antimicrob Chemother 70 (2015), 1552–1557.
26. 26 MacGowan, A.P., Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 62:Suppl. 1 (2008), 11–16.
27. 27 Castanheira, M., Mills, J.C., Costello, S.E., Jones, R.N., Sader, H.S., Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains. Antimicrob Agents Chemother 59 (2015), 3509–3517.